Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission
Copyright © 2023 Elsevier España, S.L.U. All rights reserved..
BACKGROUND: Faecal calprotectin (FC) shows an excellent correlation with endoscopic and histological activity of ulcerative colitis (UC) and it is the best predictor of clinical relapse. Our aim was to evaluate the usefulness of modifying the dose of mesalazine based on FC levels, in clinical practice.
METHODS: Retrospective, single-centre study in UC patients in clinical remission while treated with mesalazine which dosage was decreased (DOWN) or increased (UP) according to FC levels. The main endpoint was the long-term maintenance of clinical remission.
RESULTS: A total of 56 patients were included (39 DOWN, 17 UP). In the DOWN group, the median baseline dose of mesalazine was 3.6g/day and the median baseline FC was 36μg/g. After a median follow-up of 22 months, 28% required rescue therapy. The cumulative relapse-free survival after tapering was 91% and 82% at 12 and 24 months, respectively. In the UP group, the median baseline dose of mesalazine was 2.4g/day, with a median baseline FC of 524μg/g. After a median follow-up of 12 months, 29% required rescue therapy. The cumulative relapse-free survival after dose increase was 86% and 72% at 12 and 24 months, respectively.
CONCLUSIONS: Mesalazine dose modification based on FC monitoring seems to be a safe strategy in patients with UC in clinical remission, with a probability of clinical relapse around 20% at two years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - (2023) vom: 06. Okt. |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Modificación de la dosis de mesalazina en función de los niveles de calprotectina fecal en pacientes con colitis ulcerosa en remisión clínica |
|---|
| Beteiligte Personen: |
Piñero, Gisela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Calprotectina fecal |
|---|
| Anmerkungen: |
Date Revised 04.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.gastrohep.2023.09.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362999341 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362999341 | ||
| 003 | DE-627 | ||
| 005 | 20231226092420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2023.09.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362999341 | ||
| 035 | |a (NLM)37806344 | ||
| 035 | |a (PII)S0210-5705(23)00439-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Piñero, Gisela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission |
| 246 | 3 | 3 | |a Modificación de la dosis de mesalazina en función de los niveles de calprotectina fecal en pacientes con colitis ulcerosa en remisión clínica |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND: Faecal calprotectin (FC) shows an excellent correlation with endoscopic and histological activity of ulcerative colitis (UC) and it is the best predictor of clinical relapse. Our aim was to evaluate the usefulness of modifying the dose of mesalazine based on FC levels, in clinical practice | ||
| 520 | |a METHODS: Retrospective, single-centre study in UC patients in clinical remission while treated with mesalazine which dosage was decreased (DOWN) or increased (UP) according to FC levels. The main endpoint was the long-term maintenance of clinical remission | ||
| 520 | |a RESULTS: A total of 56 patients were included (39 DOWN, 17 UP). In the DOWN group, the median baseline dose of mesalazine was 3.6g/day and the median baseline FC was 36μg/g. After a median follow-up of 22 months, 28% required rescue therapy. The cumulative relapse-free survival after tapering was 91% and 82% at 12 and 24 months, respectively. In the UP group, the median baseline dose of mesalazine was 2.4g/day, with a median baseline FC of 524μg/g. After a median follow-up of 12 months, 29% required rescue therapy. The cumulative relapse-free survival after dose increase was 86% and 72% at 12 and 24 months, respectively | ||
| 520 | |a CONCLUSIONS: Mesalazine dose modification based on FC monitoring seems to be a safe strategy in patients with UC in clinical remission, with a probability of clinical relapse around 20% at two years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Calprotectina fecal | |
| 650 | 4 | |a Colitis ulcerosa | |
| 650 | 4 | |a Faecal calprotectin | |
| 650 | 4 | |a Mesalazina | |
| 650 | 4 | |a Mesalazine | |
| 650 | 4 | |a Remisión | |
| 650 | 4 | |a Remission | |
| 650 | 4 | |a Ulcerative colitis | |
| 700 | 1 | |a Mañosa, Míriam |e verfasserin |4 aut | |
| 700 | 1 | |a Calafat, Margalida |e verfasserin |4 aut | |
| 700 | 1 | |a Vayreda, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Fiorella |e verfasserin |4 aut | |
| 700 | 1 | |a Puig, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Domènech, Eugeni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g (2023) vom: 06. Okt. |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2023.09.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 10 | ||